Growth Metrics

Eli Lilly (LLY) Other Non-Current Liabilities (2016 - 2026)

Eli Lilly filings provide 18 years of Other Non-Current Liabilities readings, the most recent being $4.1 billion for Q1 2026.

  • On a quarterly basis, Other Non-Current Liabilities rose 78.51% to $4.1 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $4.1 billion, a 78.51% increase, with the full-year FY2025 number at $4.0 billion, down 2.24% from a year prior.
  • Other Non-Current Liabilities hit $4.1 billion in Q1 2026 for Eli Lilly, up from $4.0 billion in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $6.3 billion in Q3 2025 to a low of $1.7 billion in Q1 2022.
  • Median Other Non-Current Liabilities over the past 5 years was $2.3 billion (2025), compared with a mean of $2.8 billion.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 52.3% in 2022 and later skyrocketed 181.04% in 2025.
  • Eli Lilly's Other Non-Current Liabilities stood at $1.8 billion in 2022, then grew by 22.84% to $2.2 billion in 2023, then surged by 81.25% to $4.1 billion in 2024, then decreased by 2.24% to $4.0 billion in 2025, then rose by 2.9% to $4.1 billion in 2026.
  • The last three reported values for Other Non-Current Liabilities were $4.1 billion (Q1 2026), $4.0 billion (Q4 2025), and $6.3 billion (Q3 2025) per Business Quant data.